DHDan Hao

Dan Hao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dan Hao has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Xian Jiang

    Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China

    6 shared publications
  • Yue Xiao

    Department of Dermatology and Venereology, West China Hospital Sichuan University Chengdu China

    3 shared publications
  • Wei Yan

    West China Hospital, Sichuan University

    2 shared publications
  • Xiaoxue Li

    Department of Dermatology, West China Hospital, Sichuan University, Chengdu 610041, China

    2 shared publications
  • Yanmei Li

    Department of Dermatology and Venereology West China Hospital, SiChuan University SiChuan China

    2 shared publications
  • Bowen Ke

    Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

    1 shared publication

Latest Publications

  • Open Access

    Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

    by Yiyi Wang, Jingya Gao, Furong Li, Luyuan Li, Yue Xiao, Hongxiang Hu, Xiya Peng, Min Yang, Dan Hao, Wei Yan, et al.

    Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain limited. This study aimed to compare the real‐world effectiveness and safety of ADA, SEC, and UPA in PsA patients. We conducted a prospective cohort study using data from the PARWCH database. PsA patients treated with ADA, SEC, or UPA were included and followed at baseline, Week 4, Week 12, and Week 24. Skin responses were evaluated using PASI75/90. Joint outcomes—including peripheral and axial arthritis—were assessed with ACR, PsARC, and ASAS criteria. Patient‐reported pain, disease activity, and HAQ scores were also recorded. Adverse events (AEs) were monitored throughout treatment. MMRM and GLMM were used to analyze continuous and binary outcomes, respectively. A total of 187 PsA patients were included (SEC: 78; ADA: 66; UPA: 43). All three agents demonstrated comparable effectiveness in improving peripheral joint symptoms (ACR20: SEC vs. ADA, Coef = −0.29, p = 0.62; UPA vs. ADA, Coef = −0.29, p = 0.66) and axial involvement (ASAS20: SEC vs. ADA, Coef = −0.04, p = 0.81; UPA vs. ADA, Coef = −1.05, p = 0.23). UPA and SEC showed significantly greater effectiveness than ADA in improving skin lesions (PASI90: SEC vs. ADA, Coef = 1.84, p = 0.006; UPA vs. ADA, Coef = 1.53, p = 0.04). However, ADA was more effective in relieving pain compared to both UPA (Coef = 2.43, p < 0.001) and SEC (Coef = 1.21, p = 0.02). Over 24 weeks, 85 AEs were reported by 48 patients, with fatigue, rash, upper respiratory tract infection, and pruritus being the most common. No serious AEs occurred. In conclusion, UPA and SEC demonstrated balanced effectiveness across skin and joint domains, while ADA offered superior pain relief. These findings support personalized treatment strategies tailored to the clinical features of PsA patients.


  • Open Access

    Disseminated disease caused by Mycobacterium marseillense: A case report and literature review

    by Ji Mm Cheng, Jun-Yan Qu, Michael R. Hamblin, Dan Hao, Xiang Wen

    Rationale: Among numerous types of nontuberculous mycobacterial infections, Mycobacterium avium complex is a related group of species, which can cause various diseases in humans. Mycobacterium marseillense is a member of the Mycobacterium avium complex, which accounts for only a small proportion of species, but causes rare diseases affecting the lungs, lymph nodes, skin, and tendon sheath. So far, very few cases have been reported. Patient concerns: A 76-year-old male of peculiar skin infection. Metagenomic Next Generation Sequencing and bacterial culture of skin secretions revealed M marseillense. To the best of our knowledge, we report the first patient diagnosed with disseminated M marseillense infection. Here, we identified only 8 other reports of patients with M marseillense infection. Diagnoses: Disseminated M marseillense infection. Interventions: The patient was treated with clarithromycin, rifampicin, moxifloxacin, and ethambutol. Outcomes: The skin lesions of the patient showed significant improvement, and his pruritus and limb pain were notably reduced after 7 months of follow-up. Lessons: Metagenomic Next Generation Sequencing may be a useful tool to diagnose M marseillense infection, but the results should be confirmed by culture and mycobacterial identification.


  • Open Access

    Photoprotective Effects of Cannabidiol against Ultraviolet-B-Induced DNA Damage and Autophagy in Human Keratinocyte Cells and Mouse Skin Tissue

    by Yanmei Li, Dan Hao, Danfeng Wei, Yue Xiao, Lian Liu, Xiaoxue Li, Lian Wang, Yu Gan, Wei Yan, Bowen Ke, et al.

    Cannabidiol (CBD) has emerged as a phytocannabinoid with various beneficial effects for the skin, including anti-photoaging effects, but its mechanisms of action are not fully elucidated. The study assessed CBD’s photoprotective effects against acute ultraviolet B (UVB)-induced damage in HaCaT human keratinocyte cells and murine skin tissue. CBD (8 μM) alleviated UVB-induced cytotoxicity, apoptosis, and G2/M cell cycle arrest in HaCaT cells. The contents of γH2AX and cyclobutane pyrimidine dimers were decreased after CBD treatment. CBD reduced the production of reactive oxygen species and modulated the expression of antioxidant-related proteins such as nuclear factor erythroid 2-related factor 2 in UVB-stimulated HaCaT cells. Furthermore, CBD mitigated the UVB-induced cytotoxicity by activating autophagy. In addition, a cream containing 5% CBD showed effectiveness against UVB-induced photodamage in a murine model. The CBD cream improved the skin’s condition by lowering the photodamage scores, reducing abnormal skin proliferation, and decreasing expression of the inflammation-related protein cyclooxygenase-2 in UVB-irradiated skin tissue. These findings indicate that CBD might be beneficial in alleviating UVB-induced skin damage in humans. The photoprotective effects of CBD might be attributed to its modulatory effects on redox homeostasis and autophagy.


  • Topical tacrolimus reduces the severe pain of tufted angioma: Case report

    by Yue Xiao, Dan Hao, Yanmei Li, Yi Ji, Xian Jiang


  • Sweet syndrome associated with malignancies: A retrospective analysis of 25 patients from West China hospital

    by Hao Dan, Li Yanmei, Xiao Yue, Jiang Xian

    Sweet syndrome (SS), also known as acute febrile neutrophilic dermatosis, is a rare inflammatory disorder characterized by sudden onset of variably tender brightly erythematous‐to‐violaceous papules, plaques, or nodules. To clarify the frequency, clinical course, therapeutic response, and outcome of Sweet syndrome with malignancy. We conducted a retrospective review of patients diagnosed with SS between 2009 and 2019 with a diagnosis of Sweet syndrome in West China hospital. Records were analyzed for variables, clinical features, etiological factors, laboratory results, and treatment outcomes. The 25 cases under study consisted of 14 (56%) females and 11 (44%) males. Mean age was 52.2 y (range: 4‐76 y). Nodules were the commonest lesion presentation (48%), involving mostly the lower limbs (52%). Pain of lesion was identified as the most common symptom (88%), followed by fever (76%) and cough (44%). Among the patients, 52% exhibited the classic form, 48% showed the malignancy‐associated form, and 4% exhibited the drug‐induced form in the setting of malignancy. Acute myeloid leukemia was the most common malignancy, observed in 5 of 12 patients (41.6%). Anemia (P = .002) was associated with malignancy (Chi‐square test).


  • Retracted
    Open Access

    [Retracted] Association between Rosacea and Cardiovascular Diseases and Related Risk Factors: A Systematic Review and Meta‐Analysis

    by Yanmei Li, Linghong Guo, Dan Hao, Xiaoxue Li, Yujia Wang, Xian Jiang

    Background. Rosacea is a common inflammatory skin disorder. Several studies, but not all, have suggested a high prevalence of cardiovascular diseases (CVDs) in rosacea patients. This study is aimed at investigating the association between rosacea and CVDs and related risk factors. Methods. We performed a literature search through PubMed, Embase, and Web of Science databases, from their respective inception to December 21, 2019. Two reviewers independently screened the articles, extracted data, and performed analysis, following the PRISMA guidelines. Odds ratios (OR) or standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated for outcomes. The included studies’ quality was evaluated using the Newcastle Ottawa Scale (NOS). Results. The final meta‐analysis included ten studies. The pooled analysis found no association between rosacea prevalence and the incidence of CVDs (OR 0.97; 95% CI 0.86‐1.10). Rosacea was found to be significantly associated with several risk factors for CVDs (OR 1.17; 95% CI 1.05‐1.31), including hypertension (OR 1.17; 95% CI 1.02‐1.35), dyslipidemia (OR 1.34; 95% CI 1.00‐1.79), and metabolic syndrome (OR 1.72; 95% CI 1.09‐2.72). However, no association was found between rosacea and diabetes mellitus (OR 0.98; 95% CI 0.82‐1.16). Among the biological parameters, a significant association was found between rosacea and total cholesterol (SMD = 0.40; 95% CI = −0.00, 0.81; p < 0.05), low‐density lipoprotein cholesterol (SMD = 0.28; 95% CI = 0.01, 0.56; p < 0.05), and C‐reactive protein (CRP) (SMD = 0.25; 95% CI = 0.10, 0.41; p < 0.05). We found no association between rosacea and high‐density lipoprotein cholesterol (SMD = 0.00; 95% CI = −0.18, 0.18; p = 0.968) or triglycerides (SMD = 0.10; 95% CI = −0.04, 0.24; p = 0.171). Conclusions. Although no significant association was found between rosacea and CVDs, rosacea was found to be associated with several of related risk factors. Patients with rosacea should pay more attention to identifiable CVD risk factors, especially those related to inflammatory and metabolic disorders.


  • Open Access

    Sanshool improves UVB-induced skin photodamage by targeting JAK2/STAT3-dependent autophagy

    by Dan Hao, Xiang Wen, Lian Liu, Lian Wang, Xianli Zhou, Yanmei Li, Xin Zeng, Gu He, Xian Jiang

    Ultraviolet radiation is markedly increased because of pollution and the depletion of the stratospheric ozone layer. Excessive exposure to sunlight can negatively affect the skin, resulting in sunburn, photo-aging, or skin cancer. In this study, we first determined the photoprotective effect of sanshool, a major component in Zanthoxylum bungeanum, on UVB-irradiated responses in human dermal fibroblasts (HDFs) and nude mouse. We found that sanshool treatment can protect cells against the effects of UVB irradiation by (i) increasing cell viability, (ii) inhibiting MMP expression, and (iii) inducing autophagy. We also used the recombinant CSF2 or anti-CSF2 antibody co-cultured with human dermal fibroblasts (HDFs) and found that CSF2 contributes to sanshool-induced autophagy. Sanshool hindered the UVB-induced activation of JAK2-STAT3 signaling in HDFs, thereby inhibiting the expression of MMPs and activation of autophagic flux. Exposure of the dorsal skin of hairless mice to UVB radiation and subsequent topical application of sanshool delayed the progression of skin inflammation, leading to autophagy and inhibiting the activation of JAK2-STAT3 signaling. These results provide a basis for the study of the photoprotective effect of sanshool and suggest that it can be potentially used as an agent against UVB-induced skin damage in humans.